↓ Skip to main content

Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Overview of attention for article published in BMC Cancer, January 2023
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
5 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
Published in
BMC Cancer, January 2023
DOI 10.1186/s12885-022-10428-3
Pubmed ID
Authors

Yohei Harada, Akemi Sato, Hideaki Nakamura, Keita Kai, Sho Kitamura, Tomomi Nakamura, Yuki Kurihara, Sadakatsu Ikeda, Eisaburo Sueoka, Shinya Kimura, Naoko Sueoka-Aragane

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 5 100%

Demographic breakdown

Readers by professional status Count As %
Professor 1 20%
Researcher 1 20%
Unknown 3 60%
Readers by discipline Count As %
Computer Science 2 40%
Agricultural and Biological Sciences 1 20%
Unknown 2 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 January 2023.
All research outputs
#15,876,708
of 23,588,018 outputs
Outputs from BMC Cancer
#4,240
of 8,486 outputs
Outputs of similar age
#228,983
of 430,160 outputs
Outputs of similar age from BMC Cancer
#68
of 161 outputs
Altmetric has tracked 23,588,018 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,486 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 430,160 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 161 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.